Toxic epidermal necrolysis in adult patients: Experience from the West Australian Collaboration
暂无分享,去创建一个
E. Raby | S. Kumarasinghe | J. Bourke | B. Ricciardo | F. Wood | Aaron J. Frederiks | S. Rowe | Tom Cunneen
[1] Darren G. Gregory. USA: Ophthalmologic Evaluation and Management of Acute Stevens-Johnson Syndrome , 2021, Frontiers in Medicine.
[2] F. Lane,et al. Vulvovaginal involvement in Stevens‐Johnson syndrome and toxic epidermal necrolysis: management and techniques used to reduce gynecologic sequelae , 2021, International journal of dermatology.
[3] M. T. White,et al. A Cautionary Tale of Etanercept Use in Patients with Toxic Epidermal Necrolysis. , 2020, Journal of burn care & research : official publication of the American Burn Association.
[4] P. Kuo,et al. Treating toxic epidermal necrolysis with systemic immunomodulating therapies: a systematic review and network meta-analysis. , 2020, Journal of the American Academy of Dermatology.
[5] L. Held,et al. Implementation and evaluation of a care bundle for prevention of non-ventilator-associated hospital-acquired pneumonia (nvHAP) – a mixed-methods study protocol for a hybrid type 2 effectiveness-implementation trial , 2020, BMC Infectious Diseases.
[6] R. Botella-Estrada,et al. Systemic therapies for Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: a SCORTEN‐based systematic review and meta‐analysis , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.
[7] P. Wolkenstein,et al. Incidence of and mortality from epidermal necrolysis (Stevens–Johnson syndrome/toxic epidermal necrolysis) in France during 2003–16: a four‐source capture–recapture estimate , 2020, The British journal of dermatology.
[8] M. Alonso-Sardón,et al. Life-threatening dermatoses: Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Impact on the Spanish public health system (2010-2015) , 2018, PloS one.
[9] M. Jeschke,et al. Toxic Epidermal Necrolysis Spectrum Management at Sunnybrook Health Sciences Centre: Our Multidisciplinary Approach After Review of the Current Evidence , 2018, Journal of cutaneous medicine and surgery.
[10] Lan-Yan Yang,et al. Randomized, controlled trial of TNF-&agr; antagonist in CTL-mediated severe cutaneous adverse reactions , 2018, The Journal of clinical investigation.
[11] E. Phillips,et al. HLAs: Key regulators of T‐cell‐mediated drug hypersensitivity , 2018, HLA.
[12] M. Schumacher,et al. Systemic Immunomodulating Therapies for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review and Meta-analysis , 2017, JAMA dermatology.
[13] J. Silverberg,et al. Morbidity and Mortality of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in United States Adults. , 2016, The Journal of investigative dermatology.
[14] P. Dziewulski,et al. U.K. guidelines for the management of Stevens–Johnson syndrome/toxic epidermal necrolysis in adults 2016 , 2016, The British journal of dermatology.
[15] Anthony J. Johnson,et al. Acute and Chronic Ophthalmic Involvement in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis - A Comprehensive Review and Guide to Therapy. II. Ophthalmic Disease. , 2016, The ocular surface.
[16] N. Sharma,et al. Adjuvant Role of Amniotic Membrane Transplantation in Acute Ocular Stevens-Johnson Syndrome: A Randomized Control Trial. , 2016, Ophthalmology.
[17] Y. Yamaguchi,et al. Retrospective analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in 87 Japanese patients--Treatment and outcome. , 2016, Allergology international : official journal of the Japanese Society of Allergology.
[18] P. Mahar,et al. Mortality and Length of Stay in Elderly Toxic Epidermal Necrolysis Patients , 2015, The Australasian journal of dermatology.
[19] L. Medenica,et al. Stevens–Johnson syndrome and toxic epidermal necrolysis: a 20‐year single‐center experience , 2015, International journal of dermatology.
[20] P. Mahar,et al. Secondary Bacterial Infection and Empirical Antibiotic Use in Toxic Epidermal Necrolysis Patients , 2014, Journal of Burn Care & Research.
[21] A. Lin,et al. Indications and Outcomes of Amniotic Membrane Transplantation in the Management of Acute Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: A Case–Control Study , 2012, Cornea.
[22] S. Fernando. The management of toxic epidermal necrolysis , 2012, Australasian Journal of Dermatology.
[23] A. Abrantes,et al. Amniotic membrane: from structure and functions to clinical applications , 2012, Cell and Tissue Research.
[24] A. Kramer,et al. Biocompatibility index of antiseptic agents by parallel assessment of antimicrobial activity and cellular cytotoxicity. , 2008, The Journal of antimicrobial chemotherapy.
[25] G. Foulks,et al. Amniotic membrane in the surgical management of acute toxic epidermal necrolysis. , 2002, Ophthalmology.
[26] J. Roujeau,et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. , 2000, The Journal of investigative dermatology.
[27] J. Rohr,et al. Toxic epidermal necrolysis in Western Australia , 2000, The Australasian journal of dermatology.
[28] S. Tseng,et al. The effects on inhibition of corneal neovascularization after human amniotic membrane transplantation in severely damaged rabbit corneas. , 1995, Korean journal of ophthalmology : KJO.